CARDIOLOGIST Trial: Artificial Intelligence Enabled Electrocardiogram for Atrial Fibrillation Detection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25732 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of Atrial Fibrillation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development

NCT06847932

Premature Atrial Complexes Atrial Arrhythmias Artificial Intelligence (AI) +2 more

RECRUITING NA

KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation

NCT05407415

Atrial Fibrillation (AF)

ENROLLING_BY_INVITATION NA

Artificial Intelligence Use for the Detection of Atrial Fibrillation Drivers

NCT03401931

Fibrillation, Atrial To Evaluate the Intraoperative Efficiency of the AIFIB Software in the Detection of Atrial Fibrillation Driver During an Ablation Procedure

WITHDRAWN

Stanford Cardiac Invasive Electrophysiology Novel Computer Experience

NCT03549806

Atrial Fibrillation Atrial Tachycardia Atrial Flutter +1 more

COMPLETED

A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF.

NCT04045639

Atrial Fibrillation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation New Onset

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Patients randomized to intervention will have access to the screening tool.

Group Type EXPERIMENTAL

AI-enabled ECG-based Screening Tool

Intervention Type OTHER

Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.

Control

Patients randomized to control will continue routine practice.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AI-enabled ECG-based Screening Tool

Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients in emergency department or inpatient department
* Patients had at least 1 ECG
* Patients cared by non-cardiologist

Exclusion Criteria

* Patients without history of atrial fibrillation diagnosis.
* Patients without history of long-term NOAC or warfarin usage.
* Patients without history of hemorrhagic stoke or ishemic stroke.
* Patients with low eGFR (\<30 ml/min)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No